Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Evaluation of ECOG Performance Status at Diagnosis and Relapse in Patients with Acute Myeloid Leukemia

Michelle Y. Zhang, Carole Shaw, Kathryn Russell, Rutu D. Vyas, Anna B. Halpern, Jacob S. Appelbaum, Cristina Maria Ghiuzeli, Roland B. Walter, Mary-Elizabeth M. Percival

Blood (2023) 142 (Supplement 1): 2844.

https://doi.org/10.1182/blood-2023-174343

Published: 2023

Journal Articles

Class III Obesity Is Associated with Worse Overall Survival in Previously Untreated Younger Patients with Acute Myeloid Leukemia Enrolled on SWOG 1203

Michelle Y. Zhang, Megan Othus, Kerry K McMillen, Harry P. Erba, Guillermo Garcia-Manero, John Pagel, Mohamed Sorror, Mary-Elizabeth M. Percival

Blood (2023) 142 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2023-189455

Published: 2023

Journal Articles

Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort

Edna Cheung, Claire Schumann, Tian Y. Zhang, Bita Fakhri, Jason Gotlib, Michaela Liedtke, William Shomali, Gabriel Mannis

Blood (2023) 142 (Supplement 1): 5927.

https://doi.org/10.1182/blood-2023-185524

Published: 2023

Journal Articles

Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia

Jesse W. Tai, Guan Li, Kailee Tanaka, Jayakrishnan Gopakumar, Crystal Zhou, Miles Hamilton Linde, Alejandro Villar-Prados, Athreya S Rangavajhula, Aaron C Trotman-Grant, Niklas Landberg, Amy C Fan, Gabriel Mannis, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 1335.

https://doi.org/10.1182/blood-2023-187981

Published: 2023

Journal Articles

Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients

Maria Moscvin, Matthew Schwede, Gabriel Mannis, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 4231.

https://doi.org/10.1182/blood-2023-186672

Published: 2023

Journal Articles

Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks

Riya Sinha, Matthew Schwede, Ben Viggiano, David Kuo, Solomon Henry, Douglas Wood, Gabriel Mannis, Ravindra Majeti, Jonathan Chen, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 960.

https://doi.org/10.1182/blood-2023-190151

Published: 2023

Journal Articles

Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the Post-Venetoclax Era

Emma C St. Martin, Matthew Schwede, Bita Fakhri, Jason Gotlib, Michaela Liedtke, William Shomali, Tian Y. Zhang, Gabriel Mannis

Blood (2023) 142 (Supplement 1): 1490.

https://doi.org/10.1182/blood-2023-190614

Published: 2023

Journal Articles

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Ruwan Gunaratne, Crystal Zhou, Jesse W. Tai, Matthew Schwede, Kailee Tanaka, Matthew Alkaitis, Raymond Yin, Brian J. Sworder, Gabriel Mannis, Ravindra Majeti, Michael S. Khodadoust, David M. Kurtz, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 4307.

https://doi.org/10.1182/blood-2023-181459

Published: 2023

Journal Articles

The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data

Matthew Schwede, Gladys Rodriguez, Solomon Henry, Douglas Wood, Gabriel Mannis, Ravindra Majeti, Jonathan Chen, Eran Bendavid, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 958.

https://doi.org/10.1182/blood-2023-187725

Published: 2023

Journal Articles

Sole DNMT3A/TET2/ASXL1 Mutations Define a Distinct Clinical Trajectory for Patients with Clonal Hematopoiesis

Shyam Ajay Patel, William K Gerber, Rena Zheng, Shrinkhala Khanna, Lloyd Hutchinson, Jan Cerny, Brandon Dasilva, Tian Y. Zhang, Salwa Khedr, William Selove, Bruce Woda, Gregory A Abel, Patricia Minehart Miron, Anne Higgins, Jonathan M. Gerber

Blood (2023) 142 (Supplement 1): 4068.

https://doi.org/10.1182/blood-2023-182881

Published: 2023

Journal Articles

Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations

Eric Kuo, Veronica Santiago, Kailee Tanaka, Vikram Puram, Crystal Zhou, Jesse W. Tai, Gabriel Mannis, Ravindra Majeti, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 1879.

https://doi.org/10.1182/blood-2023-187644

Published: 2023

Journal Articles

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Hitomi Hosoya, Mia Carleton, Kailee L Tanaka, Brian Sworder, Vanna Hovanky, George E Duran, Tian Y. Zhang, Michael S. Khodadoust, David B. Miklos, Sally Arai, David Iberri, Michaela Liedtke, Surbhi Sidana, David M. Kurtz

Blood (2022) 140 (Supplement 1): 1546–1548.

https://doi.org/10.1182/blood-2022-160370

Published: 2022

Journal Articles

Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis

Vishesh Khanna, Tali Azenkot, Selina (Qiuying) Liu, Jason Gilbert, Edna Cheung, Kimberly Lau, Daniel A. Pollyea, Elie Traer, Brian A. Jonas, Tian Y. Zhang, Gabriel N. Mannis

Blood (2022) 140 (Supplement 1): 3294–3296.

https://doi.org/10.1182/blood-2022-166803

Published: 2022

Journal Articles

High-Efficiency Multi-Drug Functional Profiling in a Microfluidic Device Towards Personalized Predictions in Pediatric Leukemia

Evelyn Kendall Williams, Dan Y. Zhang, Ryan J Summers, Jamie Oakley, Melissa L. Kemp, Christopher C. Porter, Wilbur A. Lam

Blood (2022) 140 (Supplement 1): 7848–7849.

https://doi.org/10.1182/blood-2022-162384

Published: 2022

Journal Articles

Combining single-cell tracking and omics improves blood stem cell fate regulator identification

A. Wehling, D. Loeffler, Y. Zhang, T. Kull, C. Donato, B. Szczerba, G. Camargo Ortega, M. Lee, A. Moor, B. Göttgens, N. Aceto, T. Schroeder

Blood (2022) 140 (13): 1482–1495.

https://doi.org/10.1182/blood.2022016880

Published: 2022

Includes: Supplemental data

Journal Articles

Model-Predicted Clinical Factors Impacting Patient-Specific Response of Sickle Cells to Voxelotor in a Microfluidic Platform

Dan Y. Zhang, Melissa Azul, Wilbur A. Lam, David K. Wood, Melissa L. Kemp

Blood (2021) 138 (Supplement 1): 2033.

https://doi.org/10.1182/blood-2021-148026

Published: 2021

Journal Articles

Microfluidic Multi-Drug and Multi-Dose Functional Profiling Towards Personalized Clinical Predictions in Pediatric Leukemia

Evelyn Kendall Williams, Dan Y. Zhang, Ryan J Summers, Jamie Oakley, Christopher C. Porter, Wilbur A. Lam

Blood (2021) 138 (Supplement 1): 2960.

https://doi.org/10.1182/blood-2021-152079

Published: 2021

Journal Articles

Redefining Hyperviscosity in Acute Leukemia: Implications for Red Cell Transfusions

Jamie Oakley, Evelyn Kendall Williams, Dan Y. Zhang, Christina Caruso, Yumiko Sakurai, Reginald Tran, Melissa L. Kemp, Glen Lew, Ross M. Fasano, Wilbur A. Lam

Blood (2021) 138 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2021-146577

Published: 2021

Journal Articles

Visualizing Sickle Cell Disease Whole Blood Flow and Viscosity through Modifications to Hemoglobin Levels from a Simple Blood Transfusion

Kirby S. Fibben, Wilbur A. Lam, Dan Y. Zhang, Melissa L. Kemp, David K. Wood, Elizabeth Eiffrig

Blood (2021) 138 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2021-153386

Published: 2021

Journal Articles

Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)

Irena Tan, Matthew Schwede, Paul Phan, Raymond Yin, Tian Y Zhang, Gabriel N. Mannis

Blood (2021) 138 (Supplement 1): 1216.

https://doi.org/10.1182/blood-2021-147886

Published: 2021

NARROW

Evaluation of ECOG Performance Status at Diagnosis and Relapse in Patients with Acute Myeloid Leukemia

Class III Obesity Is Associated with Worse Overall Survival in Previously Untreated Younger Patients with Acute Myeloid Leukemia Enrolled on SWOG 1203

Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort

Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients

Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks

Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the Post-Venetoclax Era

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data

Sole DNMT3A/TET2/ASXL1 Mutations Define a Distinct Clinical Trajectory for Patients with Clonal Hematopoiesis

Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis

High-Efficiency Multi-Drug Functional Profiling in a Microfluidic Device Towards Personalized Predictions in Pediatric Leukemia

Combining single-cell tracking and omics improves blood stem cell fate regulator identification

Model-Predicted Clinical Factors Impacting Patient-Specific Response of Sickle Cells to Voxelotor in a Microfluidic Platform

Microfluidic Multi-Drug and Multi-Dose Functional Profiling Towards Personalized Clinical Predictions in Pediatric Leukemia

Redefining Hyperviscosity in Acute Leukemia: Implications for Red Cell Transfusions

Visualizing Sickle Cell Disease Whole Blood Flow and Viscosity through Modifications to Hemoglobin Levels from a Simple Blood Transfusion

Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only